单位：[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院肿瘤科
The treatment of gastrointestinal cancer has always been a crucial research area, and targeted therapy has been receiving increasing attention. At present, the effect of targeted therapy is unsatisfactory for gastric cancer. Thus, the discovery of new targets is crucial. Claudin 18.2 (CLDN18.2), a member of the claudin family, belongs to the tight junction protein family that controls the flow of molecules between cell layers. CLDN18.2 expression has been discussed in many studies. In recent years, there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362. Furthermore, CLDN18.2-specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors, such as gastric and pancreatic cancers. Considerable research has been focused on CLDN18.2. CLDN18.2, a newly discovered marker for precise targeted therapy of gastric cancer, could offer new hope for the treatment of gastric cancer.
语种：
外文
第一作者：
第一作者单位：[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Qian Niu,Jiamin Liu,Xiaoxiao Luo,et al.Future of targeted therapy for gastrointestinal cancer: Claudin 18.2[J].Oncology and Translational Medicine.2021,(3):doi:10.1007/s10330-020-0470-0.
APA：
Qian Niu,Jiamin Liu,Xiaoxiao Luo,Beibei Su&Xianglin Yuan.(2021).Future of targeted therapy for gastrointestinal cancer: Claudin 18.2.Oncology and Translational Medicine,,(3)
MLA：
Qian Niu,et al."Future of targeted therapy for gastrointestinal cancer: Claudin 18.2".Oncology and Translational Medicine ..3(2021)
